# 1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids

> **NCT01197300** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 25 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT01197300
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-25
- **Primary completion:** 2019-02-27
- **Final completion:** 2019-02-27
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01197300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01197300, "1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01197300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*